Equities analysts expect Opko Health Inc. (NASDAQ:OPK) to report earnings per share of ($0.08) for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Opko Health’s earnings, with the lowest EPS estimate coming in at ($0.10) and the highest estimate coming in at ($0.07). Opko Health posted earnings per share of ($0.12) during the same quarter last year, which would indicate a positive year over year growth rate of 33.3%. The firm is scheduled to issue its next quarterly earnings results on Thursday, March 7th.

According to Zacks, analysts expect that Opko Health will report full-year earnings of ($0.21) per share for the current year, with EPS estimates ranging from ($0.24) to ($0.17). For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.20) per share, with EPS estimates ranging from ($0.34) to ($0.09). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Opko Health.

Opko Health (NASDAQ:OPK) last announced its earnings results on Friday, November 9th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.03. Opko Health had a negative net margin of 30.24% and a negative return on equity of 8.68%. The business had revenue of $250.00 million during the quarter, compared to the consensus estimate of $264.04 million. During the same quarter last year, the firm earned ($0.08) earnings per share. The business’s revenue for the quarter was up 1.6% on a year-over-year basis.

A number of equities analysts have weighed in on the stock. Zacks Investment Research raised shares of Opko Health from a “hold” rating to a “buy” rating and set a $4.00 target price for the company in a research note on Friday, November 30th. Barrington Research reiterated a “buy” rating and set a $7.00 price target on shares of Opko Health in a report on Monday, November 12th. BidaskClub cut shares of Opko Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 8th. ValuEngine upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a report on Friday, September 7th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $20.00 price target on shares of Opko Health in a report on Tuesday, August 7th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $9.50.

In other news, CEO Phillip Md Et Al Frost purchased 10,000 shares of the business’s stock in a transaction dated Friday, September 7th. The shares were purchased at an average price of $5.57 per share, for a total transaction of $55,700.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 42.74% of the company’s stock.

Large investors have recently bought and sold shares of the company. ING Groep NV purchased a new stake in Opko Health in the second quarter worth approximately $1,575,000. BlackRock Inc. boosted its holdings in Opko Health by 38.7% in the second quarter. BlackRock Inc. now owns 29,531,554 shares of the biotechnology company’s stock worth $138,798,000 after purchasing an additional 8,237,434 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its holdings in Opko Health by 842.6% in the second quarter. Metropolitan Life Insurance Co. NY now owns 106,050 shares of the biotechnology company’s stock worth $498,000 after purchasing an additional 94,799 shares during the last quarter. Voya Investment Management LLC boosted its holdings in Opko Health by 36.5% in the second quarter. Voya Investment Management LLC now owns 124,610 shares of the biotechnology company’s stock worth $586,000 after purchasing an additional 33,289 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in Opko Health by 6.1% in the second quarter. Rhumbline Advisers now owns 337,168 shares of the biotechnology company’s stock worth $1,585,000 after purchasing an additional 19,316 shares during the last quarter. Hedge funds and other institutional investors own 26.20% of the company’s stock.

Shares of NASDAQ OPK traded down $0.28 on Wednesday, reaching $3.49. 5,445,751 shares of the company’s stock traded hands, compared to its average volume of 4,021,159. Opko Health has a 12 month low of $2.66 and a 12 month high of $6.40. The company has a market capitalization of $2.09 billion, a price-to-earnings ratio of -12.03 and a beta of 1.90. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.78 and a current ratio of 0.91.

Opko Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Read More: Understanding the different types of bonds

Get a free copy of the Zacks research report on Opko Health (OPK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.